Luca Dezzani
Luca Dezzani, MD is a medical doctor with extensive healthcare experience as a physician in clinical practice and in the pharmaceutical industry. He practiced as a physician in Hematology and Internal Medicine before joining Novartis Oncology where he served in roles at national, regional, and global levels in Europe and North America. More recently, he built and led the US Oncology medical organization at Eisai. He has a strong expertise in oncology clinical development and medical affairs, and he is passionate about the application of technology to healthcare. Luca now leads the Immuno-Oncology Franchise within the US Oncology Organization at AstraZeneca.
MedCity News
FDA approves GSK drug for endometrial cancer with specific genetic signature
The FDA approved GlaxoSmithKlie drug dostarlimab (Jemperli) for endometrial cancer that carries a particular genetic signature. The immunotherapy now joins Merck s Keytruda as the checkpoint inhibitors approved for treating endometrial cancer.
Shares0
A drug that GlaxoSmithKline acquired as part of a $5 billion deal now has FDA approval, making it the second immunotherapy of this type approved for endometrial cancer and the first for such cancers carrying a particular genetic signature.
The Thursday regulatory decision for dostarlimab covers patients with recurrent or advanced endometrial cancer that has progressed following an initial line of treatment with chemotherapy. Those cancers must have mismatch repair deficiency (dMMR), in which mutations affect the proper repair of DNA inside a cell. This genetic feature is characteristic of several types of cancer and is also found in some
Updated guidance for cancer patients during Covid-19 may help improve outcomes
Updated guidance for cancer patients during Covid-19 may help improve outcomes
New recommendations may provide reassurance for patients and their care teams, while uniquely positioning healthcare providers to help communicate this critical information to vulnerable populations.
Shares0
The Covid-19 pandemic has caused a significant disruption in cancer care due to missed screenings, biopsies and surgeries that further delayed diagnoses for certain cancers.
Now with vaccinations underway, updated guidance has been issued regarding cancer patients and Covid-19 vaccinations – these will bring us closer to addressing the effects that the pandemic has had on cancer care. As the leading cause of cancer-related deaths among both men and women in the US, lung cancer outcomes, in particular, have been heavily affected by Covid-19 worldwide.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Adam Silverman
Adam Silverman MD is the chief medical officer of Syllable. He is a passionate healthcare innovator with 30 years of experience as a physician and executive. He has a diverse work history that includes private practice, academic medicine and physician leadership in both hospital and ambulatory settings. He is a board-certified General Internist who relocated to the West Coast in 2019 to serve as the inaugural Chief Medical Officer of Syllable. He has deep accountable and value-based care, and digital health experience and has had senior leadership roles in large health systems.